Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Otorhinolaryngologic Neoplasms"
Show Display Options
Rank Status Study
1 Not yet recruiting Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer
Conditions: Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Verrucous Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Verrucous Carcinoma of the Larynx;   Tongue Cancer
Interventions: Biological: cetuximab;   Drug: cisplatin;   Radiation: external beam radiation therapy;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years